Home › Compare › DKDRF vs ABBV
DKDRF yields 4.40% · ABBV yields 3.06%● Live data
📍 DKDRF pulled ahead of the other in Year 1
Combined, DKDRF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of DKDRF + ABBV for your $10,000?
NewMed Energy - Limited Partnership engages in the exploration, development, production, and sale of petroleum, natural gas, and condensate in Israel and Cyprus. The company holds interests in the Leviathan project, which covers an area of 500 km2 located to the west of the shores of Haifa; the Block 12 that covers an area of approximately 386 km2 located in Cyprus; and the Yam Tethys project, which covers an area of 500 km2 located to the west of the shores of Ashkelon. It also holds interests in the New Ofek license that covers an area of approximately 344 km2 located in Israel; the New Yahel license, covering an area of 397.5 km2 located in Israel; and the Tanin and Karish leases covering an area of approximately 500km2 located to the west of the shores of Nahariya. The company serves independent power producers and various industrial enterprises. NewMed Energy Management Ltd. serves as the general partner of the company. The company was formerly known as Delek Drilling - Limited Partnership and changed its name to NewMed Energy - Limited Partnership in February 2022. NewMed Energy - Limited Partnership was incorporated in 1993 and is based in Herzliya, Israel. NewMed Energy - Limited Partnership is a subsidiary of Delek Energy Systems Ltd.
Full DKDRF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.